Edegem

• A study to learn how effective and safe the drug “mirabegron” is and how long it stays in the body of children aged 6 months to less than 3 … Ended
  2023-507903-74-00 5 2024-02-28 Neurogenic detrusor overactivity (NDO)
• A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder … Ended
  2022-502183-20-00 5 2024-02-26 Moderately to Severely Active Ulcerative Colitis
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• MK-7480 Multiple Ascending Dose Study in Healthy Participants Ended
  2023-508982-34-00 3 2024-02-09 Non-alcoholic steatohepatitis
• Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants Ended
  2023-504460-41-00 3 2024-01-30 Fibrostenotic Crohn’s disease
• Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects Ended
  2023-507997-41-00 3 2024-01-25 Chronic cough
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN Ended
  2023-505796-76-00 3 2024-01-18 Locally Advanced Squamous Cell Carcinoma of the Head and Neck
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 7 2024-01-09 HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Adva
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients Ended
  2024-515296-35-00 7 2023-12-06 Histologically or cytologically confirmed solid tumor of the pancreas,
• MK-1403 Single Dose Formulation PK Study Ended
  2023-507984-20-00 3 2023-11-17 Atherosclerosis
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s … Ended
  2022-502540-12-00 5 2023-11-09 Refractory Status Epilepticus (RSE)
• A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr … Ended
  2023-504168-40-00 5 2023-11-06 Prevention of invasive extraintestinal pathogenic Escherichia coli (Ex
• A study in healthy men to test how well different doses of BI 3802876 are tolerated Ended
  2023-504538-23-00 1 2023-10-24 Healthy volunteer trial
• A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep … Ended
  2022-503067-15-00 5 2023-10-02 Tuberous Sclerosis Complex (TSC) related epilepsy
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv
• A study in healthy people to test how well repeated doses of BI 3032950 are tolerated Ended
  2023-503332-40-00 3 2023-09-05 Healthy
• A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended
  2022-502647-35-00 4 2023-09-01 Non-alcoholic steatohepatitis
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A phase I study to evaluate an investigational medicinal product for the treatment of asthma, in healthy adult participants. Ended
  2023-504326-19-00 3 2023-08-03 Asthma
• A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended
  2023-505627-30-00 7 2023-07-26 Solid Neoplasm
• A phase 2a study of CR9114 in healthy adult participants Ended
  2023-505020-57-00 4 2023-07-10 Influenza virus

Showing 481–504 of 583 trials